PHAXIAM Therapeutics deploys an ambitious strategy on the phage therapy market

PHAXIAM Therapeutics announced a growth strategy focused on the rapidly evolving phage therapy market. In a webinar held on November 27, 2024, the company outlined its plans to achieve operating profitability by 2027. This strategy is based on two pillars: the traditional medical product (PTMP) model and individualized compounded therapy (IPT).

The IPT model will enable the expansion of personalized treatments internationally, targeting up to €100 million in annual revenue by 2030. In parallel, the PTMP model, supported by the GLORIA clinical study, could generate around €8 million in revenue in 2027, with similar growth potential.

By combining these approaches, PHAXIAM hopes to meet the growing demand for treatments for resistant bacterial infections, while ensuring a stable revenue stream.